E23.1: Drug-induced hypopituitarism
E23.1, drug-induced hypopituitarism, is listed as a covered diagnosis in 4 Medicare billing and coding articles that apply to 15 HCPCS Level II codes, including J1071 (Injection, testosterone cypionate, 1 mg), J3145 (Injection, testosterone undecanoate, 1 mg), J3490 (Unclassified drugs). The articles come from 3 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.
HCPCS Level II codes with E23.1 as a covered diagnosis
| Code | Description | Medicare coverage | DMEPOS fee 2026 (state range) | Articles listing it |
|---|---|---|---|---|
| J1071 | Injection, testosterone cypionate, 1 mg | Special coverage instructions apply | — | 2 |
| J3145 | Injection, testosterone undecanoate, 1 mg | Special coverage instructions apply | — | 2 |
| J3490 | Unclassified drugs | Special coverage instructions apply | — | 2 |
| J3121 | Injection, testosterone enanthate, 1 mg | Special coverage instructions apply | — | 2 |
| J1072 | Injection, testosterone cypionate (azmiro), 1 mg | Special coverage instructions apply | — | 1 |
| G0278 | Iliac and/or femoral artery angiography, non-selective, bilateral or ipsilateral to catheter insertion, performed at the same time as cardiac catheterization and/or coronary angiography, includes positioning or placement of the catheter in the distal aorta or ipsilateral femoral or iliac artery, injection of dye, production of permanent images, and radiologic supervision and interpretation (list separately in addition to primary procedure) | Carrier judgment | — | 1 |
| G2187 | Patients with clinical indications for imaging of the head: head trauma | Carrier judgment | — | 1 |
| G2188 | Patients with clinical indications for imaging of the head: new or change in headache above 50 years of age | Carrier judgment | — | 1 |
| G2189 | Patients with clinical indications for imaging of the head: abnormal neurologic exam | Carrier judgment | — | 1 |
| G2190 | Patients with clinical indications for imaging of the head: headache radiating to the neck | Carrier judgment | — | 1 |
| G2191 | Patients with clinical indications for imaging of the head: positional headaches | Carrier judgment | — | 1 |
| G2192 | Patients with clinical indications for imaging of the head: temporal headaches in patients over 55 years of age | Carrier judgment | — | 1 |
| G2193 | Patients with clinical indications for imaging of the head: new onset headache in pre-school children or younger (<6 years of age) | Carrier judgment | — | 1 |
| G2194 | Patients with clinical indications for imaging of the head: new onset headache in pediatric patients with disabilities for which headache is a concern as inferred from behavior | Carrier judgment | — | 1 |
| G2195 | Patients with clinical indications for imaging of the head: occipital headache in children | Carrier judgment | — | 1 |
Medicare policy articles listing E23.1
- A57615: Billing and Coding: Treatment of Males with Low Testosterone (Noridian Healthcare Solutions, LLC (MAC - Part A, MAC - Part B); 4 Level II codes). LCD with the same title: L36538, L39086
- A58828: Billing and Coding: Treatment of Males with Low Testosterone (Palmetto GBA (MAC - Part A, MAC - Part B); 5 Level II codes). LCD with the same title: L36538, L39086
- A57056: Billing and Coding: Aortography and Peripheral Angiography (First Coast Service Options, Inc. (MAC - Part A, MAC - Part B); 1 Level II codes). LCD with the same title: L36767
- A56612: Billing and Coding: CT of the Head (Palmetto GBA (MAC - Part A, MAC - Part B); 9 Level II codes). LCD with the same title: L34417
A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.
Other E23 diagnoses (Hypofunction and other disorders of the pituitary gland)
- E23.0 — Hypopituitarism
- E23.3 — Hypothalamic dysfunction, not elsewhere classified
- E23.6 — Other disorders of pituitary gland
- E23.7 — Disorder of pituitary gland, unspecified
Frequently asked questions
Does Medicare cover E23.1 (Drug-induced hypopituitarism)?
Medicare covers items and services, not diagnoses. 4 Medicare billing and coding articles list E23.1 as a covered diagnosis for 15 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.
Which HCPCS codes can be billed with ICD-10 E23.1?
The Level II codes from the policies most specific to this diagnosis are J1071 (Injection, testosterone cypionate, 1 mg, 2 articles); J3145 (Injection, testosterone undecanoate, 1 mg, 2 articles); J3490 (Unclassified drugs, 2 articles); J3121 (Injection, testosterone enanthate, 1 mg, 2 articles); J1072 (Injection, testosterone cypionate (azmiro), 1 mg, 1 article). Code choice depends on the item supplied; check each code's descriptor.
Which Medicare policy articles list E23.1?
A57615 (Billing and Coding: Treatment of Males with Low Testosterone); A58828 (Billing and Coding: Treatment of Males with Low Testosterone); A57056 (Billing and Coding: Aortography and Peripheral Angiography), and 1 more article.
What is ICD-10-CM code E23.1?
E23.1 is the ICD-10-CM code for drug-induced hypopituitarism, in category E23 (Hypofunction and other disorders of the pituitary gland), chapter 4: Endocrine, nutritional and metabolic diseases.
Next steps
- Run a reimbursement report for a device billed under J1071
- Watch J1071 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J1071
Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.
Chapter 4: Endocrine, nutritional and metabolic diseases · All diagnoses · HCPCS lookup